<DOC>
	<DOCNO>NCT00369447</DOCNO>
	<brief_summary>This Phase I-II study design investigate nimotuzumab ( TheraCIM h-R3 ) combination external radiation patient non-small cell lung cancer . The purpose Phase I portion study evaluate safety feasibility administration nimotuzumab palliative radiation patient unsuitable radical therapy select optimal dose Phase II component study . The primary objective Phase II portion study examine efficacy combination treatment . The Phase I component study complete . The Phase II close recruitment .</brief_summary>
	<brief_title>A Study Nimotuzumab Combination With External Radiotherapy Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This randomize , double blind , multicenter Phase II study Phase I lead-in . Patients enrol study receive external radiotherapy without nimotuzumab ( TheraCIM h-R3 ) . The objective Phase I component study evaluate safety feasibility administration nimotuzumab palliative radiation patient unsuitable radical therapy ( curative intent chemoradiation ) select optimal biologically effective dose ( BED ) Phase II component study . In Phase II component , overall survival , local systemic response rate quality life evaluate inpatient treat nimotuzumab combination palliative radiation vs. radiation alone . The Phase I component study complete . The Phase II close recruitment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm nonsmall cell lung cancer . 2 . Patients must suitable palliative radiation therapy per institutional standard . 3 . Stage IIB , III IV ( patient steroid treat , stable brain metastasis eligible ) . 4 . Patients may symptomatic asymptomatic disease 5 . Age &gt; 18 year 6 . ECOG 012 7 . Patients receive previous chemotherapy allow 8 . Haemoglobin &gt; 9g/dL ( blood transfusion increase Hb level acceptable ) 9 . Stage II/III patient must consider unsuitable radical ( standard full dose curative intent ) chemoradiation opinion either radiotherapist medical oncologist . 10 . Patients must measurable disease plan radiation field . 11 . Women childbearing potential men must agree use adequate contraception . 12 . Ability understand willingness sign write informed consent document Exclusion criterion Phase I Phase II : 1 . Patients receive investigational agent 2 . Previous treatment antiEGFR drug ( ) 3 . History allergic reaction attribute compound similar chemical biologic composition nimotuzumab agent use study . 4 . Prior thoracic radiotherapy condition 5 . Prior chemotherapy within 4 week enrolment 6 . Lesions suitable radiotherapy 7 . Patients know sero positive HIV 8 . Patients uncontrolled hypercalcemia 9 . Patients progressive untreated brain metastasis treat brain metastasis unable discontinue steroid 10 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , severe cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement opinion investigator 11 . Pregnant breastfeed woman 12 . Any concurrent active malignancy nonmelanoma skin cancer carcinoma situ cervix ; patient prior malignancy eligible provide prior malignancy clinically confused diagnosis NSCLC opinion treat oncologist ; particular , evidence current disease activity respect prior malignancy 13 . Life expectancy le 8 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Nimotuzumab</keyword>
	<keyword>TheraCIM</keyword>
	<keyword>h-R3</keyword>
	<keyword>YM BioSciences</keyword>
	<keyword>Radiation</keyword>
	<keyword>Non small cell lung cancer , Stage IIb , III IV</keyword>
</DOC>